CN112205614A - Pleurotus tuber-regium sclerotium health-care product and preparation method and application thereof - Google Patents
Pleurotus tuber-regium sclerotium health-care product and preparation method and application thereof Download PDFInfo
- Publication number
- CN112205614A CN112205614A CN202010935829.6A CN202010935829A CN112205614A CN 112205614 A CN112205614 A CN 112205614A CN 202010935829 A CN202010935829 A CN 202010935829A CN 112205614 A CN112205614 A CN 112205614A
- Authority
- CN
- China
- Prior art keywords
- pleurotus tuber
- regium
- parts
- health
- sclerotium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000149440 Lentinus tuber-regium Species 0.000 title claims abstract description 80
- 241001558929 Sclerotium <basidiomycota> Species 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims description 14
- 238000004519 manufacturing process Methods 0.000 title description 3
- 239000000843 powder Substances 0.000 claims abstract description 62
- 230000036541 health Effects 0.000 claims abstract description 34
- 229920002752 Konjac Polymers 0.000 claims abstract description 31
- 235000010485 konjac Nutrition 0.000 claims abstract description 28
- 241000233866 Fungi Species 0.000 claims abstract description 26
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims abstract description 25
- 239000000252 konjac Substances 0.000 claims abstract description 25
- 235000013373 food additive Nutrition 0.000 claims abstract description 14
- 239000002778 food additive Substances 0.000 claims abstract description 14
- 235000013312 flour Nutrition 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 241001312219 Amorphophallus konjac Species 0.000 claims abstract 5
- 230000001954 sterilising effect Effects 0.000 claims description 17
- 108010011485 Aspartame Proteins 0.000 claims description 16
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 16
- 229960003438 aspartame Drugs 0.000 claims description 16
- 235000010357 aspartame Nutrition 0.000 claims description 16
- 239000000605 aspartame Substances 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 claims description 15
- 108010053775 Nisin Proteins 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 235000010297 nisin Nutrition 0.000 claims description 15
- 239000004309 nisin Substances 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 14
- 238000005303 weighing Methods 0.000 claims description 14
- 238000004659 sterilization and disinfection Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- 244000247812 Amorphophallus rivieri Species 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- 206010060755 Type V hyperlipidaemia Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 238000011629 hyperlipidemia animal model Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000008802 xuezhikang Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
- A23L19/115—Konjak; Konntaku
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a Pleurotus tuber-regium sclerotium health-care product which comprises the following components in parts by weight: 50-60 parts of pleurotus tuber-regium sclerotium powder, 20-30 parts of konjac flour, 10-20 parts of black fungus powder and 1-5 parts of food additives. The health product takes the Pleurotus tuber-regium and the konjac flour as main raw materials, exerts the health care effect of the Pleurotus tuber-regium to the maximum extent, and develops the market of the Pleurotus tuber-regium.
Description
Technical Field
The invention relates to the technical field of health products, in particular to a Pleurotus tuber-regium sclerotium health product and a preparation method and application thereof.
Background
The sclerotium of Pleurotus tuber-regium is a high temperature edible sclerotium of fungi native to tropical and subtropical zones, and has biological morphology and structure similar to those of Poria of eight delicacies of Chinese medicine, and is rich in active substances such as Pleurotus tuber regium polysaccharide, terpene and ketone. The Pleurotus tuber-regium sclerotium can be used for treating dysentery, gastropathy, constipation, fever, common cold, edema, chest pain, smallpox, asthma, hypertension, mastitis, diabetes, coronary heart disease, tumor, etc., also can promote fetal development, improve survival rate of premature infant, improve immunity, and resist tumor, and is a good medicinal fungus.
At present, the pleurotus tuber-regium is rarely applied worldwide, most pleurotus tuber-regium is planted and processed into medicinal materials for sale, and few reports about preparing pleurotus tuber-regium into health-care products are reported.
Therefore, how to provide a health care product of sclerotium of Pleurotus tuber-regium and apply the health care product to daily life is a problem which needs to be solved urgently by technical personnel in the field.
Disclosure of Invention
In view of the above, the invention provides a Pleurotus tuber-regium sclerotium health product which takes Pleurotus tuber regium and konjaku flour as main raw materials, exerts the health care effect of Pleurotus tuber regium to the maximum extent, and develops the market of Pleurotus tuber regium.
In order to achieve the purpose, the invention adopts the following technical scheme:
a Pleurotus tuber-regium sclerotium health product comprises the following components in parts by weight: 50-60 parts of pleurotus tuber-regium sclerotium powder, 20-30 parts of konjac flour, 10-20 parts of black fungus powder and 1-5 parts of food additives.
As a preferred technical scheme, the Pleurotus tuber-regium sclerotium health-care product comprises the following components in parts by weight: 54 parts of pleurotus tuber-regium sclerotium powder, 26 parts of konjac flour, 17 parts of black fungus and 3 parts of food additive.
The technical effect that above-mentioned technical scheme reaches is:
the pleurotus tuber-regium sclerotium powder mainly contains substances such as a plurality of monomeric compounds, protein, amino acid, mineral substances, polysaccharide, unsaturated fatty acid, trace elements necessary for human bodies and the like, wherein the substances playing a main pharmacological role are amino acid, secondary metabolite, protein, volatile oil component, active substances such as fatty acid, polysaccharide and the like, and mineral elements such as potassium, calcium, magnesium and the like, and the effective components can effectively achieve the effects of reducing blood sugar, blood fat and treating coronary heart disease;
konjak contains glucan, is a high molecular compound, has strong water absorption, can expand 80-100 times in volume after absorbing water, and is easy to digest and absorb after eating. Can adsorb cholesterol and bile acid, and has certain effects in lowering blood pressure and reducing cardiovascular diseases; the konjak also contains soluble dietary fiber and is very effective in inhibiting the rise of blood sugar after meal, so the konjak fine powder and the product thereof are ideal blood sugar reducing food for diabetics and can reduce the burden of pancreatic islets after application; moreover, the Pleurotus tuber-regium sclerotium powder is not easy to dissolve in water, and after the konjac flour is added, the solubility of the Pleurotus tuber regium sclerotium powder in water can be increased, the Pleurotus tuber regium sclerotium powder is convenient to take orally, and the drug effect of the Pleurotus tuber regium sclerotium powder is improved;
the black fungus has the effects of benefiting qi, nourishing blood, moistening lung, relieving cough, resisting blood coagulation, lowering blood pressure, resisting cancer, promoting blood circulation, benefiting qi, moistening lung, nourishing brain, reducing weight, cooling blood, stopping bleeding, astringing intestine, promoting blood circulation, strengthening will, nourishing face and the like;
therefore, the pleurotus tuber-regium, the konjac and the black fungus are compounded together, so that the pleurotus tuber-regium, the konjac and the black fungus have a remarkable effect of assisting in reducing blood fat, the efficacy of the pleurotus tuber-regium is improved by adding the konjac and the black fungus, the three have synergistic effects, and the effects of reducing blood sugar and blood fat are achieved together.
As a preferred embodiment of the present invention, the food additive comprises: aspartame and nisin, wherein the weight ratio of the aspartame to the nisin is (1-2): (3-4).
The technical effect that above-mentioned technical scheme reaches is: aspartame is rapidly metabolized into aspartic acid, phenylalanine and methanol in vivo, even if a large amount of aspartame is ingested, the aspartame cannot be retained in blood and cannot cause harm to human bodies, and the aspartame is a natural functional oligosaccharide, has higher sweetness and can obviously improve the mouthfeel of health care products;
nisin is a metabolite of microorganisms of the genus Streptococcus lactis and can be obtained by fermentation and extraction of Streptococcus lactis. The nisin has the advantages that the nisin can be degraded by proteolytic enzymes in the digestive tract of a human body, is not absorbed into the body in the original form, is a safer preservative, does not change the normal flora of the intestinal tract like antibiotics, causes the drug resistance of other commonly used antibiotics, and further does not have cross resistance with other antibiotics.
A preparation method of a Pleurotus tuber-regium sclerotium health-care product comprises the following steps:
1) weighing: weighing the pleurotus tuber-regium sclerotium powder, the konjac powder, the black fungus powder and the food additive according to the weight part ratio for later use;
2) mixing: mixing and uniformly stirring the raw materials weighed in the step 1) to obtain a mixture;
3) and (3) sterilization and drying: sterilizing the mixture, and freeze-drying to obtain Pleurotus tuber-regium sclerotium health product.
The technical effect that above-mentioned technical scheme reaches is: the components are stirred and mixed uniformly, so that the components can become a uniform and stable system, and the nutrition distribution is more uniform; the sterilization can kill the microorganisms in the mixture, and the safety of the health food is improved; the drying can effectively remove the water in the water, and prevent the mass propagation of microorganisms caused by excessive water or excessive humidity.
As a preferable technical scheme of the invention, in the step 3), the sterilization is performed at the temperature of 115-125 ℃ for 20-25 min.
In a preferable embodiment of the present invention, in the step 3), the drying is performed at-40 to-50 ℃ for 1 to 2 hours.
The invention also provides application of the Pleurotus tuber-regium sclerotium health-care product prepared by the preparation method in preparation of an auxiliary blood fat reducing medicine.
In conclusion, the Pleurotus tuber-regium sclerotium health care product disclosed by the invention has the effect of obviously assisting in reducing blood fat, and develops the market of Pleurotus tuber-regium sclerotium health care products.
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
A Pleurotus tuber-regium sclerotium health product comprises the following components in parts by weight: 50g of pleurotus tuber-regium sclerotium powder, 30g of konjac powder, 19g of black fungus powder, 0.25g of aspartame and 0.75g of nisin.
The preparation method of the Pleurotus tuber-regium sclerotium health-care product comprises the following steps:
1) weighing: weighing the pleurotus tuber-regium sclerotium powder, the konjac powder, the black fungus powder and the food additive according to the weight for later use;
2) mixing: mixing and uniformly stirring the raw materials weighed in the step 1) to obtain a mixture;
3) and (3) sterilization and drying: sterilizing the mixture at 115 deg.C for 20min, and drying at-40 deg.C for 1h to obtain Pleurotus tuber-regium sclerotium health product.
Example 2
A Pleurotus tuber-regium sclerotium health product comprises the following components in parts by weight: 60g of pleurotus tuber-regium sclerotium powder, 20g of konjac powder, 15g of black fungus powder, 5/3g of aspartame and 10/3g of nisin.
The preparation method of the Pleurotus tuber-regium sclerotium health-care product comprises the following steps:
1) weighing: weighing the pleurotus tuber-regium sclerotium powder, the konjac powder, the black fungus powder and the food additive according to the weight for later use;
2) mixing: mixing and uniformly stirring the raw materials weighed in the step 1) to obtain a mixture;
3) and (3) sterilization and drying: sterilizing the mixture at 125 deg.C for 25min, and drying at-50 deg.C for 2h to obtain Pleurotus tuber-regium sclerotium health product.
Example 3
A Pleurotus tuber-regium sclerotium health product comprises the following components in parts by weight: 56g of pleurotus tuber-regium sclerotium powder, 24g of konjac powder, 17g of black fungus powder, 0.9g of aspartame and 2.1g of nisin.
The preparation method of the Pleurotus tuber-regium sclerotium health-care product comprises the following steps:
1) weighing: weighing the pleurotus tuber-regium sclerotium powder, the konjac powder, the black fungus powder and the food additive according to the weight for later use;
2) mixing: mixing and uniformly stirring the raw materials weighed in the step 1) to obtain a mixture;
3) and (3) sterilization and drying: sterilizing the mixture at 121 deg.C for 21min, and drying at-45 deg.C for 1.5h to obtain Pleurotus tuber-regium sclerotium health product.
Example 4
A Pleurotus tuber-regium sclerotium health product comprises the following components in parts by weight: 52g of pleurotus tuber-regium sclerotium powder, 27g of konjac powder, 20g of black fungus powder, 0.2g of aspartame and 0.8g of nisin.
The preparation method of the Pleurotus tuber-regium sclerotium health-care product comprises the following steps:
1) weighing: weighing the pleurotus tuber-regium sclerotium powder, the konjac powder, the black fungus powder and the food additive according to the weight for later use;
2) mixing: mixing and uniformly stirring the raw materials weighed in the step 1) to obtain a mixture;
3) and (3) sterilization and drying: sterilizing the mixture at 118 deg.C for 22min, and drying at-48 deg.C for 1.7h to obtain Pleurotus tuber-regium sclerotium health product.
Example 5
A Pleurotus tuber-regium sclerotium health product comprises the following components in parts by weight: 60g of pleurotus tuber-regium sclerotium powder, 25g of konjac powder, 10g of black fungus powder, 2g of aspartame and 3g of nisin.
The preparation method of the Pleurotus tuber-regium sclerotium health-care product comprises the following steps:
1) weighing: weighing the pleurotus tuber-regium sclerotium powder, the konjac powder, the black fungus powder and the food additive according to the weight for later use;
2) mixing: mixing and uniformly stirring the raw materials weighed in the step 1) to obtain a mixture;
3) and (3) sterilization and drying: sterilizing the mixture at 118 deg.C for 22min, and drying at-48 deg.C for 1.7h to obtain Pleurotus tuber-regium sclerotium health product.
Example 6 modeling
Refer to "Notification about 9 evaluation methods of health care function such as the method of evaluating antioxidant function of issue" (No. 2012/107 of State food and drug administration, Accessory 6 auxiliary method of evaluating hypolipidemic function).
High-sugar and high-fat feed: the maintenance feed is added with 20.0% of cane sugar, 15% of lard, 1.2% of cholesterol, 0.2% of sodium cholate, 12% of casein, 1.8% of calcium hydrophosphate, 0.6% of stone powder and 0.2% of salt. Both the maintenance feed and the high-sugar and high-fat feed are purchased from Beijing Huafukang biotech GmbH [ production license number: SCXK (Jing) 2014-.
Establishing a mixed hyperlipidemia animal model: SPF-grade male SD rats 40 purchased from beijing vintonia experimental animal technology ltd [ license number: SCXK (Jing) 2016-.
After 7d of laboratory adaptive feeding, 2 groups were randomly divided, namely 10 blank control groups, 30 model groups, and the blank groups were fed with maintenance feed, the model groups were fed with high-sugar and high-fat feed, and the food and water were freely taken, after 7d of continuous feeding, orbital veins were sampled, and the serum TC, TG and LDL-C, HDL-C levels were measured, and the results are shown in Table 1:
TABLE 1
Note:**compared with the model control group, P is less than 0.01.
As can be seen from table 1, the model group and the blank control group were compared: the serum triglyceride is increased, the serum total cholesterol or the low density lipoprotein cholesterol is increased, and the difference is significant (P is less than 0.05), and then the animal model of the mixed hyperlipidemia is established.
Example 7 verification of hypoglycemic efficacy
The normal dose of the Pleurotus tuber-regium health product prepared in example 3 as a test article per day for an adult is 20g, and the mouse of the model group constructed in example 6 as a subject takes 10 times of the normal dose, i.e., the mouse takes 3.3 g/(Kg.d).
The 30 mice in the model group in example 6 were randomly divided into 3 groups of 10 mice each:
test group: mice were gavaged daily with the product of example 3;
blank control group: the mice are infused with distilled water with the same volume as the stomach every day
Positive control group for Xuezhikang: the mice were gavaged daily at 0.1 g/kgBW;
each group of rats had free access to water and food. Continuously administering for one week, and measuring TC, TG, LDL-C, HDL-C level in blood serum the next day after the last administration; the results are shown in Table 2;
TABLE 2
Note: p < 0.05 compared to the model group in example 6; p < 0.01 compared to the model group in example 6.
As can be seen from Table 2, the TC, TG and LDL-C levels in the tested animal groups are all significantly reduced compared with the model group, which shows that the Pleurotus tuber-regium sclerotium health product of example 3 has an obvious effect of assisting in reducing blood fat.
Example 8
Control group 1: the following components are prepared into the health care product by the same method as the example 3: 20g of pleurotus tuber-regium sclerotium powder, 40g of konjac powder, 30g of black fungus powder, 2.5g of aspartame and 7.5g of nisin;
control group 2: the following components are prepared into the health care product by the same method as the example 3: 70g of pleurotus tuber-regium sclerotium powder, 10g of konjac powder, 5g of black fungus powder, 3g of aspartame and 12g of nisin;
control group 3: removing the konjac powder in the example 3, and adjusting the amount of the pleurotus tuber-regium sclerotium powder to 48.16g, the amount of the black fungus powder to 14.62g, the aspartame to 0.774g and the nisin to 1.806 g;
modeling was performed according to the method of example 6, and the model group was subjected to the experiment according to the method of example 7, with the modeling results shown in table 3 and the experimental results shown in table 4;
TABLE 3
TABLE 4
Note: p < 0.05 compared to the model group in example 6; p < 0.01 compared to the model group in example 6.
As can be seen from Table 4, the ratio of the components greatly affects the effect of reducing blood fat, and the results of the comparison groups 1 and 2 show that when the ratio of the components is out of the range of the invention, the effect of assisting in reducing blood fat is reduced, which shows that the ratio of the components in the invention achieves outstanding technical effects; as can be seen from the control group 3, the addition of konjaku flour also affected the efficacy of the Pleurotus tuber-regium kernel powder, so konjaku flour has a synergistic effect on Pleurotus tuber-regium kernel powder.
The embodiments in the present description are described in a progressive manner, each embodiment focuses on differences from other embodiments, and the same and similar parts among the embodiments are referred to each other. The device disclosed by the embodiment corresponds to the method disclosed by the embodiment, so that the description is simple, and the relevant points can be referred to the method part for description.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (7)
1. The health-care product of the sclerotium of the pleurotus tuber-regium is characterized by comprising the following components in parts by weight: 50-60 parts of pleurotus tuber-regium sclerotium powder, 20-30 parts of konjac flour, 10-20 parts of black fungus powder and 1-5 parts of food additives.
2. The Pleurotus tuber-regium sclerotium health care product according to claim 1, is characterized by comprising the following components in parts by weight: 54 parts of pleurotus tuber-regium sclerotium powder, 26 parts of konjac flour, 17 parts of black fungus and 3 parts of food additive.
3. The Pleurotus tuber-regium sclerotium health product according to any one of claims 1-2, wherein the food additive comprises: aspartame and nisin, wherein the weight ratio of the aspartame to the nisin is (1-2): (3-4).
4. The preparation method of the Pleurotus tuber-regium sclerotium health care product according to claim 3, which is characterized by comprising the following steps:
1) weighing: weighing the pleurotus tuber-regium sclerotium powder, the konjac powder, the black fungus powder and the food additive according to the weight part ratio for later use;
2) mixing: mixing and uniformly stirring the raw materials weighed in the step 1) to obtain a mixture;
3) and (3) sterilization and drying: sterilizing the mixture, and freeze-drying to obtain Pleurotus tuber-regium sclerotium health product.
5. The method for preparing Pleurotus tuber-regium sclerotium health product according to claim 4, wherein in step 3), the sterilization is performed at 115-125 ℃ for 20-25 min.
6. The preparation method of the Pleurotus tuber-regium sclerotium health product according to claim 4, wherein in the step 3), the drying is carried out at-40 to-50 ℃ for 1-2 h.
7. The application of the Pleurotus tuber-regium sclerotium health-care product prepared by the preparation method of any one of claims 4-6 in preparing an auxiliary blood fat-reducing medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010935829.6A CN112205614A (en) | 2020-09-08 | 2020-09-08 | Pleurotus tuber-regium sclerotium health-care product and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010935829.6A CN112205614A (en) | 2020-09-08 | 2020-09-08 | Pleurotus tuber-regium sclerotium health-care product and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112205614A true CN112205614A (en) | 2021-01-12 |
Family
ID=74049155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010935829.6A Pending CN112205614A (en) | 2020-09-08 | 2020-09-08 | Pleurotus tuber-regium sclerotium health-care product and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112205614A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113142552A (en) * | 2021-04-27 | 2021-07-23 | 东华理工大学 | Pleurotus tuber-regium rice syrup for relieving cough and moistening lung and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1559603A (en) * | 2004-02-26 | 2005-01-05 | 温宝华 | Hunai Mushroom sclerotium used for treating diabotes and its preparation |
| CN105166191A (en) * | 2015-10-20 | 2015-12-23 | 温炫翀 | Pleurotus tuber tea and preparation method thereof |
| CN110279019A (en) * | 2019-08-12 | 2019-09-27 | 广西民族师范学院 | A kind of relieving cough and moistening lung mushroom alternative tea and processing method |
| CN111514250A (en) * | 2020-05-28 | 2020-08-11 | 中国检验检疫科学研究院 | Compound beverage with blood fat reducing effect and preparation method and application thereof |
-
2020
- 2020-09-08 CN CN202010935829.6A patent/CN112205614A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1559603A (en) * | 2004-02-26 | 2005-01-05 | 温宝华 | Hunai Mushroom sclerotium used for treating diabotes and its preparation |
| CN105166191A (en) * | 2015-10-20 | 2015-12-23 | 温炫翀 | Pleurotus tuber tea and preparation method thereof |
| CN110279019A (en) * | 2019-08-12 | 2019-09-27 | 广西民族师范学院 | A kind of relieving cough and moistening lung mushroom alternative tea and processing method |
| CN111514250A (en) * | 2020-05-28 | 2020-08-11 | 中国检验检疫科学研究院 | Compound beverage with blood fat reducing effect and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 刘阿娟，等: "虎奶菇菌核多糖的溶液粘度及构象研究", 《食品工业科技》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113142552A (en) * | 2021-04-27 | 2021-07-23 | 东华理工大学 | Pleurotus tuber-regium rice syrup for relieving cough and moistening lung and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1105123B1 (en) | Pharmaceutical compositions containing lipase inhibitors and chitosan | |
| DE60301677T2 (en) | Pharmaceutical and food compositions containing a di- or oligosaccharide that enhances insulin release | |
| US20110177175A1 (en) | Dietary fiber compositions | |
| KR100597235B1 (en) | Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis | |
| KR101614574B1 (en) | Composition of Diabetes-Improving Effective Constituents by Fermentation Products of the Trifoliate Orange | |
| JP3720496B2 (en) | Novel pectin and emulsion containing the same | |
| CN112889987A (en) | Food composition, tablet candy and application | |
| CN112205614A (en) | Pleurotus tuber-regium sclerotium health-care product and preparation method and application thereof | |
| JP2008266223A (en) | Formulation for ameliorating excessive sensitivity to cold | |
| CN111513273A (en) | Konjak functional food and preparation method thereof | |
| KR101859166B1 (en) | A composition for removing hangover comprising an herb extract including ginseng | |
| JP5702713B2 (en) | Pharmaceutical composition for promoting adiponectin production and food useful therefor | |
| KR102000170B1 (en) | Food compositions for reducing body fat and improving intestinal function | |
| JPH08198769A (en) | Excessive nutrition absorption inhibitor and composition containing the same | |
| Jung et al. | L-ascorbic acid addition to chitosan reduces body weight in overweight women | |
| KR101645535B1 (en) | Composition containing glucosamine with anti-immflammatory and pain repression effect | |
| KR20230145464A (en) | Drug composition for treating hyperlipidemia and method for producing the same | |
| JP3142192B2 (en) | Blood lipid improving agent and composition containing the same | |
| CN1184902C (en) | Liver-protecting functional food made up by using ligustrum fruit and silkworm chrysalis and its preparation method | |
| CN1806671A (en) | Konjaku flour dispersible tablet | |
| JPH11147828A (en) | Absorption inhibitor against cholesterol and lipid | |
| KR20200131603A (en) | Feed composition for immunity comprising extract from yeast, food composition for immunity comprising extract from yeast and manufactuaring method for extract from yeast using ultrasonics wave | |
| CN110801474A (en) | Composition for preventing and treating constipation and application thereof | |
| CN108669530A (en) | A kind of Hericium erinaceus composition, tablet and preparation method conducive to stomach health | |
| JP3183754B2 (en) | Arteriosclerosis inhibitor and composition containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210112 |
|
| RJ01 | Rejection of invention patent application after publication |